Table 2. Comparisons of the available meta-analyses evaluating the relationship between TRT and CV outcomes.

Variable	Calof et al (2005) [18]	Haddad et al (2007) [19]	Fernández-Balsells et al (2010) [20]	Xu et al (2013) [22]	Corona et al (2014) [21]
Inclusion criteria
No. of trials included	19	30	51	27	74
No. of patients analyzed	1,084	1,642	2,679	2,944	5,464
Primary endpoint of MACE incidence					O
Primary endpoint of all CV event incidence	O	O		O
Primary endpoint of all adverse TRT events			O
Time restriction (>12 weeks)	O			O
Age restriction (≥45 years old)	O
All available RCTs reporting adverse CV events		O			O
Cardiovascular event analysis
All CV events	O	O		O	O
Serious adverse events (including MACE)				O
MACE					O
AMI	O	O	O		O
Acute coronary syndrome	O				O
Coronary bypass surgery	O		O		O
Stroke	O				O
New heart failure					O
Arrhythmias	O		O		O
CV mortality			O	O	O

TRT: testosterone replacement therapy, CV: cardiovascular, MACE: major adverse cardiovascular events, RCTs: randomized controlled trials, AMI: acute myocardial infarction.